Evaluation of Blood-Brain Barrier Breakdown in a Mouse Model of Mild Traumatic Brain Injury

Summary

A method was developed to visualize dye extravasation due to blood-brain barrier (BBB) breakdown by administering two fluorescent dyes to mice at different time points. The use of glycerol as a cryoprotectant facilitated immunohistochemistry on the same sample.

Abstract

Fluorescent dyes are used to determine the extent of dye extravasation that occurs due to blood-brain barrier (BBB) breakdown. Labeling with these dyes is a complex process influenced by several factors, such as the concentration of dyes in the blood, permeability of brain vessels, duration of dye extravasation, and reduction in dye concentration in the tissue due to degradation and diffusion. In a mild traumatic brain injury model, exposure to blast-induced shock waves (BSWs) triggers BBB breakdown within a limited time window. To determine the precise sequence of BBB breakdown, Evans blue, and fluorescein isothiocyanate-dextran were injected intravascularly and intracardially into mice at various time points relative to BSW exposure. The distribution of dye fluorescence in brain slices was then recorded. Differences in the distribution and intensity between the two dyes revealed the spatiotemporal sequence of BBB breakdown. Immunostaining of the brain slices showed that astrocytic and microglial responses correlated with the sites of BBB breakdown. This protocol has broad potential for application in studies involving different BBB breakdown models.

Introduction

Blood-brain barrier (BBB) breakdown and dysfunction are caused by systemic inflammation, infections, autoimmune diseases, injuries, and neurodegenerative diseases¹. In mild traumatic brain injury (mTBI) resulting from exposure to blast-induced shock waves (BSWs), a significant correlation has been observed between the intensity of BSWs and the amount of fluorescent dye leakage due to BBB breakdown^2,3,4. One notable feature of BBB breakdown in mTBI is that it begins immediately or within a few hours after exposure to BSWs and is usually a transient process that lasts for about a week before delayed, chronic neurological disorders emerge^3,5,6,7. Although the details remain unclear, BBB breakdown is part of the long-lasting pathological cascade and may also serve as a prognostic factor in mTBI⁶. Therefore, understanding the spatial and temporal distributions of BBB breakdown in the brain is important.

Fluorescent dyes are used to determine the extent of BBB breakdown^3,8. Because the blood concentration of the dyes and the magnitude and extent of BBB breakdown change over time, caution is required when interpreting images of dye extravasation. For instance, the absence of dye extravasation does not necessarily indicate the absence of BBB breakdown. No BBB breakdown may be detected before or after an increase in the dye's blood concentration. Even if the dye successfully accumulated where BBB breakdown occurred, it may have been lost over time after the breakdown ceased. In general, water-soluble and biologically inert substances are quickly excreted in the urine⁹. Therefore, to determine whether BBB breakdown occurs at a specific time, the most reliable results are obtained when a fluorescent dye is administered into the bloodstream for a short period immediately before fixing the animal. Commercially available fluorescein isothiocyanate (FITC)-dextran with a specific molecular weight should be used in this manner.

Evans blue is a widely recognized blue azo dye with a strong affinity for serum albumin. The dye exhibits red fluorescence when excited by green light in biological systems². Due to its inert nature, the Evans blue-serum albumin complex remains in the blood for up to 2 h, making it a useful 69 kDa tracer for labeling regions with a compromised BBB for at least this duration^10,11. Therefore, it is important to consider potential uncertainties surrounding the pharmacokinetics and toxicity of Evans blue⁹. However, a recent study showed that Evans blue continues to accumulate in areas where the BBB is absent or disrupted⁷. This feature enabled Evans Blue to record the history of the BBB breakdown, while FITC-dextran was used to record the BBB breakdown at a specific time point after the BSW exposure. Although Evans blue can be administered intravenously or intraperitoneally¹⁰, intravenous administration is preferred for time-sensitive experiments. This study aimed to demonstrate the use of Evans blue and FITC-dextran to detect the spatiotemporal distribution of BBB breakdown following exposure to BSW.

Second, the study presented a technique for freezing brain slices after observing the fluorescence of BBB breakdown and preparing thinner slices suitable for immunohistochemical procedures. The use of glycerol as a mounting medium and cryoprotectant simplifies the immunohistochemistry process. By comparing images of BBB breakdown with those from immunohistochemistry, the spatiotemporal distribution of BBB breakdown can be correlated with the tissue response of the same sample.

Protocol

All experiments were conducted in accordance with the ethical guidelines for animal experiments established by the National Defense Medical College (Tokorozawa, Japan). The study protocol was approved by the Committee for Animal Research at the National Defense Medical College (approval no. 23011-1). Male C57BL/6J mice aged 8 weeks and weighing 19-23 g were used in this study. As illustrated in Figure 1, a single Evans blue injection and FITC-dextran perfusion were performed at various time points in relation to a single BSW exposure. Details of the reagents and equipment used are listed in the Table of Materials.

1. Anesthesia

NOTE: This is a modified protocol that increases the amount of medetomidine by 2.5 times compared with the original one¹². The dosages for medetomidine hydrochloride, midazolam, and butorphanol were 0.75 mg/kg, 4 mg/kg, and 5 mg/kg, respectively.

1. Prepare a mixture of medetomidine hydrochloride (75 µg/mL), midazolam (400 µg/mL), and butorphanol (500 µg/mL) in physiological saline.
2. Administer the mixture intraperitoneally to anesthetize the mouse (10 µL/g)¹³.
3. After approximately 5-10 min, verify sufficient anesthesia by observing the lack of tail pinch and pedal withdrawal reflexes.
4. Keep the mouse warm until it recovers from the effects of anesthesia.

2. BSW exposure

NOTE: An in-house shock tube was used in this study¹⁴.

1. Anesthetize the mouse as described in step 1.
2. Position the mouse 5 cm away from the exit end of the shock tube, ensuring its body axis is parallel to but not aligned with the tube's axis.
3. Deliver a single BSW exposure with a peak overpressure of 25 kPa to the head.
   NOTE: Keep the mouse warm until it recovers from the effects of anesthesia. Regularly monitor the condition of the treated mouse. If signs of distress, such as difficulty feeding or drinking, hunching, or prolonged abnormal appearance without signs of recovery, are observed, euthanize the mouse and terminate the experiment early. Avoid administering analgesics, as they may potentially affect the glial response.

3. Evans blue injection into the tail vein

NOTE: Evans blue solution should be administered intravenously without anesthesia. In the presence of anesthesia, the dye often does not penetrate the body sufficiently, likely due to decreased blood pressure and body temperature¹³. Evans blue was administered at a dose of 100 mg/kg.

1. Prepare the Evans blue solution (4% w/v in saline) in a microtube, then vortex and store it in the dark before use.
2. Inject the solution into the tail vein (2.5 µL/g)¹³.

4. Transcardial perfusion with FITC-dextran solution and fixation

1. Add heparin to phosphate-buffered saline (PBS) to obtain a concentration of 1 U/mL, then add FITC-dextran to the heparinized PBS to achieve a concentration of 3 mg/mL.
2. Completely dissolve the FITC-dextran powder before use. To do this, gently shake the solution for 30 min or more. Before use, carefully check for any undissolved FITC-dextran powder. If any remains, continue shaking until it is completely dissolved.
3. Anesthetize the mouse as described in step 1.
4. Proceed with the standard perfusion fixation protocol using a peristaltic pump^15,16. First, perfuse with heparinized PBS containing FITC-dextran for 2 min at a rate of 4.0 mL/min. Then, perfuse with 10% formalin neutral buffer solution or 4% paraformaldehyde-PBS for 2 min at a rate of 4.0 mL/min, followed by 8 min at a rate of 3.5 mL/min.
5. Carefully remove the brain using surgical scissors and tweezers^15,16. After dissection, post-fix the brain overnight in the same fixative (i.e., 10% formalin neutral buffer solution or 4% paraformaldehyde-PBS) at 4 °C.
6. On the following day, replace the fixative with PBS.

5. Brain tissue processing

NOTE: Even if perfusion fixation is complete, Evans blue and FITC-dextran may disperse into the buffer. Therefore, the procedures leading up to step 6.8 should be completed within a week after perfusion fixation. Additionally, avoid exposing the sample to light.

1. Prepare a 24-well plate with 500 µL of 20% glycerol in phosphate buffer (PB; pH 7.4) in each well.
2. Using a brain slicer, cut the brain coronally into 12 slices, each 1 mm thick.
3. Transfer each slice into the corresponding well of the 24-well plate and store it at 4 °C for at least 2 h.
4. Replace the solution with 50% glycerol-PB and store it at 4 °C for at least 2 h.
5. Finally, replace the solution with 100% glycerol. For immediate microscopic observation, allow the slices to stand for at least 2 h at room temperature or store them at 4 °C. The slices will now be translucent and ready for microscopic observation.

6. Fluorescence measurement of dye extravasation

NOTE: Fluorescence labeling efficiency varies from mouse to mouse. Therefore, fluorescence intensity needs to be normalized. Fluorescence values are expressed relative to those within the gigantocellular reticular nucleus (GRN) because this region is minimally affected by BSW treatment.

1. Add 500 µL of glycerol to the bottom of a 35-mm glass-bottom dish.
2. Transfer the slice to the glycerol solution and cover its surface with a coverglass.
3. Remove excess glycerol from the edge of the coverglass.
4. Measure the fluorescence intensity of the slice under a fluorescence microscope.
5. After microscopic measurement, return the slice to the well.
6. Repeat the measurement for all 12 slices.
7. Add 500 µL of PB to each well and store the 24-well plate at 4 °C overnight; on the following day, the slices will be saturated with 50% glycerol-PB.
8. Replace the solution with 30% glycerol-PB and store it at 4 °C for at least 2 h.
9. Perform the procedures in step 7 within a few weeks.

7. Cryosectioning and immunohistochemistry

1. Prepare a 24-well plate by adding 1000 µL of a mixture of equal volumes of tissue freezing medium and 30% glycerol-PB to well 1. Then, add 1000 µL of tissue freezing medium to well 2.
2. Transfer the slice to well 1 and shake the plate at 4 °C for 1 h.
3. Transfer the slice to well 2 and shake the plate at 4 °C for 1 h.
4. Quickly freeze the slice with isopentane using dry ice, taking care not to bend the slice. Store the slices at -80 °C until cryosectioning.
5. Cryosection the slice to a thickness of 6 µm. After drying on the microscope slide, store the sections at -80 °C.
6. For antigen retrieval¹⁷, immerse the sections in 10 mM sodium citrate (pH 6.0), heat to 100 °C once, and then maintain at 98 °C for 1 h.
7. Wash the sections extensively in distilled water. The sections are now ready for immunohistochemical staining.

Results

Figure 1A shows the time course of dye injection in relation to the onset of BSW, with a peak overpressure of 25 kPa. In the 'Post' protocol, Evans blue solution was administered intravascularly 2 h before FITC-dextran perfusion, which was conducted 6 h, 1 day, 3 days, and 7 days after BSW exposure. In the 'Pre' protocol, Evans blue solution was injected immediately before BSW exposure. In the 'Post' protocol, the concentration of Evans blue is expected to reach its maximum approximately 2 h...

Discussion

A novel double-labeling technique using Evans blue and FITC-dextran was used to accurately visualize the precise spatiotemporal distribution of BBB breakdown in a single brain. In the low-intensity BSW model, noticeable variations in the extent, location, and degree of dye extravasation were observed in examined brains (Figure 2 and Figure 3). Between-dye mismatches revealed that BBB breakdown commenced approximately 3 h after BSW exposure, with substantial remo...

Materials

List of materials used in this article

Name	Company	Catalog Number	Comments
10% Formalin Neutral Buffer Solution	FUJIFILM Wako Chemicals	062-01661
Anti GFAP, Rabbit	DAKO-Agilent	IR524
Anti Iba1, Rabbit	FUJIFILM Wako Chemicals	019-19741
Chicken anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488	Thermo Fisher Scientific	A-21200
Cryo Mount	Muto Pure Chemicals	33351	tissue freezing medium
Domitor	Orion Corporation		medetomidine
Donkey anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 546	Thermo Fisher Scientific	A10040
Evans Blue	Sigma-Aldrich	E2129
Falcon 24-well Polystyrene Clear Flat Bottom Not Treated Cell Culture Plate, with Lid, Individually Wrapped, Sterile, 50/Case	CORNING	351147
Fluorescein isothiocyanate–dextran average mol wt 40,000	Sigma-Aldrich	FD40S	FITC-dextran
Glass Base Dish 27mm (No.1 Glass)	AGC TECHNO GLASS	3910-035	35 mm glass bottom dish
IX83 Inverted Microscope	OLYMPUS
MAS Hydrophilic Adhesion Microscope Slides	Matsunami Glass	MAS-04
Matsunami Cover Glass (No.1) 18 x 18mm	Matsunami Glass	C018181
Midazolam Injection 10mg [SANDOZ]	Sandoz
Paraformaldehyde EMPROVE ESSENTIAL DAC	Merck Millipore	1.04005.1000
Peristaltic Pump	ATTO	SJ-1211 II-H
RODENT BRAIN MATRIX Adult Mouse, 30 g, Coronal	ASI INSTRUMENTS	RBM-2000C	brain slicer
Vetorphale	Meiji Animal Health	VETLI5	butorphanol